CLDI
- Calidi Biotherapeutics Inc.
()
Overview
Company Summary
Calidi Biotherapeutics Inc. (CLDI) is a biotechnology company that specializes in the development and commercialization of novel cell-based immunotherapies for the treatment of cancer. Their primary focus is on the engineering and manufacturing of allogeneic, or off-the-shelf, cell-based therapies using a unique proprietary platform technology called StemVacs.
Calidi Biotherapeutics aims to revolutionize cancer treatment by leveraging the power of the immune system to fight and eradicate tumors effectively. They utilize stem cell technology to develop these cell-based immunotherapies that have the potential to target a wide range of cancers.
The StemVacs platform technology allows for the engineering of immune cells derived from stem cells to express specific tumor-targeting receptors called chimeric antigen receptors (CARs). These CAR-engineered immune cells, also known as CAR-T cells, are designed to recognize and bind to cancer cells, leading to their destruction by the patient's immune system.
Calidi Biotherapeutics' approach has several advantages over traditional CAR-T therapies. Firstly, they use allogeneic cells, which means they can be manufactured in large batches and made available "off-the-shelf" without the need for individualized cell collection from each patient. This significantly reduces the time and cost associated with treatment.
Additionally, their StemVacs platform allows for the generation of CAR-T cells with enhanced tumor-targeting capabilities and increased persistence within the body. These features may improve the effectiveness and durability of the immunotherapies, potentially leading to better clinical outcomes for cancer patients.
Through their research and development efforts, Calidi Biotherapeutics is working towards advancing their cell-based immunotherapies and expanding their product pipeline to target different types of cancers. Their ultimate goal is to provide safe and effective treatments that can help address the unmet medical needs of cancer patients worldwide.